(Correcting first name to Hal, not Hall)
LONDON, Jan 19 (Reuters) - GlaxoSmithKline said on
Wednesday that Hal Barron will end his position as chief
scientific officer in August after less than five years to run a
new privately owned start-up biotech company.
Tony Wood will become CSO designate and assume full
accountability for Research and Development (R&D) on Aug. 1.
Barron will become a GSK non-executive director on Aug. 1,
with additional responsibilities to support R&D, GSK said. He
joined GSK in January 2018.
Barron is joining Altos Labs, a new biotech company based in
San Francisco, California, focused on the biology of cellular
rejuvenation programming with the goal of reversing disease, GSK
said.
(Reporting by Josephine Mason; editing by Jason Neely)